Quality of gastric ulcer healing evaluated by endoscopic ultrasonography.
OBJECTIVE
To evaluate the quality of gastric ulcer healing after different antiulcer treatment by endoscopic ultrasonography (EUS).


METHODS
The patients were divided into three groups, and received lansoprazole, amoxicillin and clarithromycin for 1 wk. Then group A took lansoprazole combined with tepreton for 5 wk, group B took lansoprazole and group C took tepreton for 5 wk. Endoscopy and EUS were performed before and 6 wk after medication.


RESULTS
There was no significant difference in cumulative healing rate to S stage between the groups (89%, 82% vs 83%, P>0.05). The rate of white scar formation was significantly higher in group A than in groups B and C (67%, 36%, 50%, P<0.05). The average contraction rates of the width of ulcer crater, length of disrupted muscularis propria layer and hypoechoic area were higher in group A than in groups B and C (0.792+/-0.090, 0.660+/-0.105 vs 0.668+/-0.143, P<0.05). The hypoechoic area disappeared in four cases of group A, one of group B and two of group C. The percentage of hypoechoic area disappearance was higher in group A than in the other two groups (44%, 9% vs 17%, P<0.05). Gastric ulcer healing was better in group A.


CONCLUSIONS
The combined administration of proton-pump inhibitors and mucosal protective agent can improve gastric ulcer healing.
Si
Jian-Min
JM
Gastroenterology Laboratory, Institute of Clinical Medicine, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, Zhejiang Province, China. sijm@163.net
Cao
Qian
Q
Wu
Jia-Guo
JG
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000293:Adolescent; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D017291:Clarithromycin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D019160:Endosonography; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013276:Stomach Ulcer / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology*; D014945:Wound Healing / Q000187:drug effects*
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D064747:Lansoprazole; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole